End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age

por Castellsagué, X, Muñoz, N, Pitisuttithum, P, Ferris, D, Monsonego, J, Ault, K, Luna, J, Myers, E, Mallary, S, Bautista, O M, Bryan, J, Vuocolo, S, Haupt, R M, Saah, A
Publicado 2011

A delayed dose of quadrivalent human papillomavirus vaccine demonstrates immune memory in HIV-1-infected men

por Ellsworth, G.B., Lensing, S.Y., Ogilvie, C.B., Lee, J.Y., Goldstone, S.E., Berry-Lawhorn, J.M., Jay, N., Stier, E.A., Logan, J.S., Einstein, M.H., Saah, A., Mitsuyasu, R.T., Aboulafia, D., Palefsky, J.M., Wilkin, T.J.
Publicado 2018

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

por Villa, L L, Costa, R L R, Petta, C A, Andrade, R P, Paavonen, J, Iversen, O-E, Olsson, S-E, Høye, J, Steinwall, M, Riis-Johannessen, G, Andersson-Ellstrom, A, Elfgren, K, Krogh, G von, Lehtinen, M, Malm, C, Tamms, G M, Giacoletti, K, Lupinacci, L, Railkar, R, Taddeo, F J, Bryan, J, Esser, M T, Sings, H L, Saah, A J, Barr, E
Publicado 2006